Ironwood Pharmaceuticals (IRWD) Non-Current Receivables (2018 - 2022)

Ironwood Pharmaceuticals has disclosed Non-Current Receivables across 5 years of filings, most recently posting $14.6 million for Q4 2022.

• Non-Current Receivables for Q4 2022 came in at $14.6 million, down 39.21% year-over-year; the trailing twelve-month figure through Dec 2022 was $14.6 million (down 39.21% YoY), and the FY2022 annual result was $14.6 million, down 39.21% from the prior year.
• Non-Current Receivables came in at $14.6 million for Q4 2022 at Ironwood Pharmaceuticals, up from $14.4 million in the prior quarter.
• In the past five years, Non-Current Receivables ranged from a high of $32.6 million in Q4 2019 to a low of $14.1 million in Q1 2022.
• The 5-year median for Non-Current Receivables is $23.2 million (2020), against an average of $22.1 million.
• Across the five-year window, Non-Current Receivables jumped 55.22% in 2019 and plunged 39.98% in 2022, its largest moves.
• Ironwood Pharmaceuticals' Non-Current Receivables stood at $21.0 million in 2018, then surged by 55.22% to $32.6 million in 2019, then slipped by 28.21% to $23.4 million in 2020, then increased by 2.55% to $24.0 million in 2021, then plunged by 39.21% to $14.6 million in 2022.
• The last three Non-Current Receivables figures came in at $14.6 million (Q4 2022), $14.4 million (Q3 2022), and $14.3 million (Q2 2022), per Business Quant data.